Sarcomes SEAL (KCP-330-020) A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS) Paris
VADS INDUCE-3 (GSK-209229) Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (INDUCE-3) Paris CHRISTOPHE LE TOURNEAU
VADS INDUCE-4 (GSK-209227) A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination With Pembrolizumab and 5FU-Platinum Chemotherapy Versus Placebo in Combination With Pembrolizumab Plus 5FU-Platinum Chemotherapy for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. Paris CHRISTOPHE LE TOURNEAU
Appareil Digestif AMEBICA - Prodige 38 Randomised Phase II/III Study, Assessing the Safety and Efficacy of Modified Folfirinox Versus Gemcis in Locally Advanced, Unresectable and/or Metastatic Bile Duct Tumours. Saint-Cloud
Appareil Digestif PACHA 01 Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases - A Randomized Phase II/III Trial Saint-Cloud
Hématologie Leucémie AML LI-1 A PROGRAMME OF DEVELOPMENT FOR OLDER PATIENTS WITH ACUTE MYELOID LEUKAEMIA AND HIGH RISK MYELODYSPLASTIC SYNDROME Saint-Cloud JACQUES VARGAFTIG
Pédiatrie Tumeurs cérébrales SIOP EPENDYMOMA II An International Clinical Program for the Diagnosis and Treatment of Children, Adolescents and Young Adults With Ependymoma Paris FRANCOIS DOZ